IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two more abbreviated new drug applications (ANDAs) to the US FDA.
IGI President and CEO Charlie Moore commented, “We are excited to announce that we successfully developed and submitted two more ANDAs. Our experienced team of development professionals is focused on our mission, to build a portfolio of topical drug products for IGI.” The development of ANDA products has successfully been integrated into the Company’s ongoing contract services business.
IGI will hold a conference call at 4:30 pm ET on Monday, November 21, 2011 to discuss 3 rd quarter 2011 results.
The Company invites you to listen to the call by dialing 1-866-510-0712. International participants should call 1-617-597-5380. The passcode for the conference call is 61633550.This call is being webcast by Thomson and can be accessed at IGI's website at www.igilabs.com. About IGI Laboratories, Inc. IGI Laboratories is focused in the development and commercialization of products for the dermatology market. IGI Laboratories, Inc. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," "possible," "one time," "provides an opportunity," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Actual results may differ materially from these expectations due to changes in global political, economic, business, competitive, market and regulatory factors or IGI Laboratories, Inc.’s ability to implement business strategies. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.